Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Bertram PittGerasimos FilippatosRajiv AgarwalStefan D AnkerGeorge L Bakris Ellen BurgessAmer JosephPeter KolkhofChristina NowackPatrick SchloemerLuis M Ruilopenull null

Published in: The New England journal of medicine (2021)

Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).

Keyphrases

cardiovascular events
type diabetes
chronic kidney disease
cardiovascular disease
coronary artery disease
glycemic control
insulin resistance
randomized controlled trial
double blind
clinical trial
mesenchymal stem cells
metabolic syndrome
bone marrow
skeletal muscle
smoking cessation